Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Aegerion Pharmaceuticals Inc

CUSIP: 00767E902 | 6 institutional holders

Quarters

Q3 2016 Q2 2016 Q1 2016 Q4 2015 Q3 2015

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile